The Next Wave of Obesity Innovation: Where Science, Market Trends, and Data Collide

by Katerina Grigoriou

Obesity Innovator_Next Wave of Innovation_April 2025.pdf

Download PDF • 5.72MB

MARKET INFLECTION

Obesity treatment is one of the most exciting frontiers in drug development today, and the unmet need is staggering. According to the World Obesity Atlas 2023, over 1 billion people globally live with obesity (BMI > 30kg/m2), a number expected to double by 2035. The economic impact? Nearly $2 trillion in 2020, projected to exceed $4 trillion by 2035, factoring in healthcare costs and lost productivity.

Despite its prevalence, obesity care has been historically overlooked. The establishment of the American Board of Obesity Medicine in 2011 was a step toward closing this gap. Yet, even as obesity prevalence doubled from 1990 to 2022, treatment innovation struggled to gain traction. Between 1990 and 2020, seven new weight-loss drugs were approved, but three were later withdrawn due to safety concerns, and another is not intended for long-term use. This history of setbacks reinforced skepticism around pharmacological interventions, creating an additional hurdle for market adoption. The breakthrough success of Wegovy and Zepbound has begun shifting this narrative, but overcoming historical biases remains critical for future progress. 

WHAT'S IN THE PIPELINE

Wegovy and Zepound have cemented GLP-1 receptor agonists (GLP-1 RAs) as the backbone of Obesity treatment. But science tells us we can do even better. What’s next?

Oral formulations could expand the obesity treatment market significantly, addressing the needs of patients hesitant about injections while offering manufacturing and logistical benefits that improve global access.

The Next Scientific Frontiers

The future of obesity treatment isn’t just about more weight loss; it’s about better weight loss. Emerging mechanisms include:

• Leptin Sensitization & Amylin Agonists: Addressing metabolic adaptation and lean mass preservation

• Activin Antagonism: Exploring bone and muscle health alongside weight loss

• Fat Composition Modulation (e.g. Adipo Therapeutics): Investigating adipose tissue remodeling for improved metabolic health

• Genetic Medicine: Long-term solutions aiming to correct the metabolic dysregulation at the root of obesity

• Weight Loss Maintenance: Innovations targeting long-term metabolic adaptation to prevent weight regain, an area where current therapies fall short

  
  

These developments signal a shift from simply achieving weight loss to sustaining it while preserving overall health. As we move beyond GLP-1s, the future of obesity treatment will be defined by personalized, holistic approaches that address the complexity of the disease.

PRECISION OBESITY MEDICINE

Obesity is not a one-size-fits-all disease. It is a highly complex, multi-factorial condition driven by a dynamic interplay of metabolic, genetic, environmental, and behavioral factors. Multiple metabolic pathways regulate weight, and these pathways are not static – they shift and adapt in response to weight loss, diet, and treatment interventions. The next wave of obesity therapies must account for these complexities, tailoring treatment approaches to individual patient needs.

As research advances, treatment strategies will likely segment by:

Severity of Disease	Early-stage metabolic dysfunction vs advanced obesity with comorbidities
Weight Loss Needs	Patients needing moderate vs significant weight reduction
Age & Gender	Addressing muscle and bone health in older populations, particularly postmenopausal women, and tackling the unique challenges of pediatric obesity, where early intervention could have lifelong benefits
Comorbidities	Developing therapies that specifically target cardiovascular health, type 2 diabetes, or metabolic dysfunction in tandem with obesity treatment

Obesity specialists already approach treatment this way, but emerging science and new tools will accelerate precision medicine across the broader healthcare landscape.

REAL-WORLD DATA

Clinical trials provide a foundation, but real-world data (RWD) is essential for understanding long-term obesity treatment outcomes. We’re already seeing broader data collection on the impact of anti-obesity medications (AOMs) on cardiovascular disease, metabolic dysfunction, and sleep apnea.

However, significant weight bias remains. Many healthcare providers still view obesity as a lifestyle choice rather than a chronic disease. The lack of emphasis on long-term prevention in healthcare systems means payers remain hesitant to cover AOMs. RWD can provide the evidence necessary to shift policy and reframe obesity treatment as essential, not elective.

THE PATH FORWARD

The dedication of scientists over the decades have brought us to an exciting place with an obesity pipeline rich with potential. As a result, the obesity treatment landscape is evolving rapidly. We stand at a pivotal moment, where the right decisions today will shape the future of obesity care for generations. The industry must move beyond a singular focus on weight loss and embrace a broader vision of metabolic health. To truly redefine obesity care:

• We must innovate beyond GLP-1s, targeting diverse pathways that personalize treatment and address long-term metabolic adaptation

• We must break barriers to access by leveraging real-world data to shift policy and overcome outdated biases

• We must champion a new paradigm – one where obesity treatment is proactive, personalized, and fully integrated into healthcare

This next era of obesity care is about more than just shedding pounds – it’s about transforming lives. The science is advancing, the market is shifting, and the momentum is undeniable. Now is the time to seize the opportunity and reimagine what’s possible in obesity treatment!

Written by Katerina Grigoriou, a life sciences strategist obsessed with bringing commercial thinking into early drug development. Read more of her insights at Queen of NPP.